MarginsXMarginsX
Home › Markets › Health Care › SNGX

Soligenix Inc. (SNGX)

SNGX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.2882
-10.22% on the day
Market cap
$6.7M
Nano cap
Revenue · 2024
$119K
-85.8% on 2023
Net income · 2024
-$8.3M
-6925.1% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/812796/000110465926037701/0001104659-26-037701-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerSNGX on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0000812796
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2024

LineValue
Revenue$119K
Net income-$8.3M
Operating income-$9.4M
Net margin-6925.1%
Operating margin-7907.7%
Revenue growth-85.8%
Cash$7.8M
Total assets$9.0M
P/E (computed)Net income was not positive
P/S (computed)56.4×

Warning signs

Cash runway
13.2 months
$9.0M cash at September 30, 2026
Share count, 1 year
+131.7%
2025-10-31 to 2026-10-30 · +3502.7% over 3 years
Going-concern doubt
Yes
10-Q filed November 6, 2026
Insider net buying, 12 months
$20K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"To mitigate the conditions that raise substantial doubt about the Company's ability to continue as a going concern, the Company's plans include securing: additional capital, potentially through a combination of public or private equity offerings and strategic transactions, including potential alliances and drug product collaborations; additional proceeds from government contract and grant programs; and additional pro"
10-Q 2026-11-06
Cash and burn$9.0M cash; operating cash flow -$2.1M a quarter.Report 2026-09-30
Shares outstanding23,368,754 (2026-10-30); 10,086,130 a year earlier; 10,378,238 three years earlier. 3y figure adjusted for splits (1-for-16 overall).Cover page 2026-10-30
Reverse splits, 3 years1; latest 1-for-16 on 2024-06-06Source 2024-06-06
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 3 424B5 takedowns, 1 at the marketLatest 2026-01-23
Exchange deficiency notices, 12 months1 (8-K item 3.01)8-K 2026-06-12
AuditorCherry Bekaert LLP, Tampa, Florida, United StatesPCAOB Form AP 2026-04-01
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $20K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$1.1M-$1.4M$9.0MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q2 2026
2026-06-30
Not filed-$2.0M-$1.7M$9.8MNo debt tagsNeeds four quarters10-Q 2026-08-07
Q1 2026
2026-03-31
Not filed-$2.8M-$2.4M$6.0MNo debt tagsNeeds four quarters10-Q 2026-05-08
Q4 2025
2025-12-31
Not filed-$2.9M-$2.7M$7.9MNo debt tagsNeeds four quarters10-K 2026-03-31
Q3 2025
2025-09-30
Not filed-$2.5M-$2.9M$10.5MNo debt tagsNeeds four quarters10-Q 2026-11-06
Q2 2025
2025-06-30
Not filed-$2.7M-$2.7M$5.1MNo debt tagsNeeds four quarters10-Q 2026-08-07
Q1 2025
2025-03-31
Not filed-$3.0M-$1.8M$7.3MNo debt tagsNeeds four quarters10-Q 2026-05-08
Q4 2024
2024-12-31
$0-$3.0M-$2.2M$7.8M$0$119K10-K 2026-03-31

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32026-11-06
Latest annual report10-K2026-03-31
Latest quarterly / interim10-Q2026-11-06
Latest current report8-K2026-09-21
Latest proxyDEFA14A2026-08-03

Source: SEC EDGAR submissions feed, 1,006 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.9%
1 month-3.0%
3 months-15.8%
Year to date-76.1%
1 year-76.8%
From 52-week high-80.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
TCRTAlaunos Therapeutics Inc.$1.60-1.84%$6.7M
TPSTTempest Therapeutics Inc.$0.3418-10.50%$6.8M
ADXNAddex Therapeutics Ltd$3.83-5.67%$6.5M
XCURExicure Inc.$1.07-0.93%$7.0M
ENVBEnveric Biosciences Inc.$1.44-4.95%$6.4M
TOVXTheriva Biologics Inc.$0.1400-2.85%$6.4M
LGVNLongeveron Inc.$2.14-14.06%$7.2M
IMRNImmuron Limited$0.8996+2.23%$7.3M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier